LAUSR

Abstract The purpose was to evaluate the effects of dienogest on Korean women with endometriosis. A cross-sectional questionnaire-based survey was conducted for 100 premenopausal women. They had taken or were taking 2 mg of dienogest daily. We assessed the pelvic pain score and quality-of-life (QOL) score before and after taking dienogest as well as the prevalence of short-term (≤12 weeks) and long-term adverse effects (>52 weeks). Patients were classified into three groups: dienogest treatment immediately following surgery (A), dienogest treatment for a recurrence of endometriosis after surgery (B), or dienogest treatment without any surgery (C). In groups A and C, the median pain score (from 5 to 0, p <.001; from 7 to 1.5, p <.001) and median QOL score (from 10 to 5, p = .002; from 7.5 to 6.5, p = .008) were significantly decreased. Irregular bleeding and decreased menstrual flow were more prevalent in patients with dienogest intake of fewer than 12 weeks, while amenorrhea, weight gain, hair loss, and dorsal pain were more prevalent in patients with dienogest treatment of over 52 weeks. Accordingly, proper counseling is necessary when prescribing dienogest. 摘要 本研究目的是评估地诺孕素对韩国子宫内膜异位症患者的治疗效果。我们对100名绝经前妇女进行了横断面问卷调查。她们曾每天或目前正每天服用2毫克的地诺孕素。我们计算了服用地诺孕素之前和之后的骨盆疼痛分数和生活质量（QOL）分数, 以及短期（≤12周）和长期（> 52周）服用地诺孕素副作用的的发生率。患者分为三组：手术后立即服用地诺孕素治疗（A）, 手术后子宫内膜异位症复发的地诺孕素治疗（B）, 仅地诺孕素治疗, 未手术（C）。在A组和C组中, 中位疼痛分数（从5到0, p <.001;从7到1.5, p <.001）中位QOL分数（从10到5, p = .002;从7.5到6.5, p = .008）显著降低。在地诺孕素服用少于12周的患者中, 不规则出血和月经量减少更为普遍, 而在地诺孕素治疗超过52周的的患者中, 闭经, 体重增加, 脱发和背部疼痛更为普遍。因此, 在开地诺孕素处方前适当的咨询是很必要的。